Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | ![]() Biomed Industries Announces Triple IGF-1/GLP-1/GIP Receptor Agonist NA-931 for ObesityBy: Biomed Industries Inc. Biomed is presenting its research results at the upcoming international conferences: NA-931, formulated for oral administration, will be in Phase 2B clinical trials in the upcoming months. As a result of its novel triple action, NA-931 significantly reduces body fat while preserving muscle mass. Moreover, NA-931 demonstrates a notable reduction in other adverse events commonly associated with existing treatments. "We have made a significant discovery as to the synergic actions of the three major growth hormone receptors and agonists that lead to the remarkable results of NA-931 for the treatment of obesity." said Lloyd Tran, Founder and CEO of Biomed Industries, Inc. He added, "This research, spanning over two decades, has yielded breakthroughs in various disease areas, including Alzheimer's Disease, ALS, Major Depressive Disorder, and rare conditions such as Rett Syndrome and Fragile X. This innovative platform holds promise for developing novel therapies for neurological and metabolic diseases, for which there are no viable treatments currently." About Biomed Industries, Inc.: Biomed Industries, Inc. is a pioneering biopharmaceutical company dedicated to developing and commercializing novel drug therapeutics to address unmet medical needs. The company's research team has developed a new platform of drugs targeting Alzheimer's disease, ALS, Major Depressive Disorder (MDD), Diabetes, Obesity, Metabolic dysfunction- For further information, please visit Biomed Industries' official website: https://www.biomedind.com CONTACT Michael Willis Biomed Industries, Inc. San Jose, CA 95131 USA Tel. 800-824-5135 Email: media@biomedind.com End
|
|